Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
PubMed
35241246
DOI
10.1016/j.jchf.2021.11.006
PII: S2213-1779(21)00583-7
Knihovny.cz E-zdroje
- Klíčová slova
- SGLT-2 inhibitors, clinical trials, heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction,
- MeSH
- diabetes mellitus 2. typu * komplikace farmakoterapie MeSH
- fibrilace síní * MeSH
- funkce levé komory srdeční MeSH
- glifloziny * farmakologie terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- natriuretický peptid typu B terapeutické užití MeSH
- peptidové fragmenty MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- srdeční selhání * MeSH
- tepový objem MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- glifloziny * MeSH
- natriuretický peptid typu B MeSH
- peptidové fragmenty MeSH
OBJECTIVES: This report describes the baseline clinical profiles and management of DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial participants and how these compare with those in other contemporary heart failure with preserved ejection fraction trials. BACKGROUND: The DELIVER trial was designed to evaluate the effects of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on cardiovascular death, heart failure (HF) hospitalization, or urgent HF visits in patients with HF with mildly reduced and preserved left ventricular ejection fraction (LVEF). METHODS: Adults with symptomatic HF and LVEF >40%, with or without type 2 diabetes mellitus, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and evidence of structural heart disease were randomized to dapagliflozin 10 mg once daily or matching placebo. RESULTS: A total of 6,263 patients were randomized (mean age: 72 ± 10 years; 44% women; 45% type 2 diabetes mellitus; 45% with body mass index ≥30 kg/m2; and 57% with history of atrial fibrillation or flutter). Most participants had New York Heart Association functional class II symptoms (75%). Baseline mean LVEF was 54.2 ± 8.8% and median NT-proBNP of 1,399 pg/mL (IQR: 962 to 2,210 pg/mL) for patients in atrial fibrillation/flutter compared with 716 pg/mL (IQR: 469 to 1,281 pg/mL) in those who were not. Patients in both hospitalized and ambulatory settings were enrolled, including 10% enrolled in-hospital or within 30 days of a hospitalization for HF. Eighteen percent of participants had HF with improved LVEF. CONCLUSIONS: DELIVER is the largest and broadest clinical trial of this population to date and enrolled high-risk, well-treated patients with HF with mildly reduced and preserved LVEF. (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [NCT03619213]).
Cardiac Sciences Department King Saud University Riyadh Saudi Arabia
Cardiovascular Center Tam Anh hospital Tan Tao University Vietnam
Cardiovascular Division Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA
Cardiovascular Division Instituto de Pesquisa Clínica de Campinas Campinas SP Brazil
Centro de Estudios Clínicos de Querétaro Querétaro México
Clínica Vesalio San Borja Peru
Department Cardiology Medical University Lodz Lodz Poland
Department of Noninvasive Cardiology National Cardiology Hospital Sofia Bulgaria
Division of Cardiac Surgery St Michael's Hospital University of Toronto Toronto Canada
Duke University Medical Center Durham North Carolina USA
General University Hospital Charles University Prague Czech Republic
Haga Teaching Hospital The Hague Netherlands
Institut de Cardiologie de Montréal Université de Montréal Montréal Québec Canada
Kinshukai Hanwa Daini Senboku Hospital Osaka JapanHeart and Vascular Center
Northwestern University Feinberg School of Medicine Chicago Illinois USA
Saint Luke's Mid America Heart Institute Kansas City Missouri USA
Semmelweis University Budapest Hungary
University of Cordoba Cordoba Argentina
University of Glasgow Glasgow Scotland UK
University of Groningen Groningen the Netherlands
University of Medicine Pharmacy Science and Technology G E Palade Târgu Mureș Romania
University of Utah Medical Center Salt Lake City Utah USA
Citace poskytuje Crossref.org
ClinicalTrials.gov
NCT03619213
